This strong genetic effect can explain the observed methylation differences between MS patients and controls in all studied cell types, i.e., CD14+ monocytes, CD19+ B cells, CD4+ T cells, and CD8+ T cells. The gene discussed is CD8A; the disease is myeloid sarcoma.